

Phase 2a clinical development of Vutiglabridin, a disease-modifying drug for Parkinson’s disease through PON2-mediated autophagy activation

Glaceum Inc.



NEUROLOGY	Phase 2
Product Type	Small molecule
Indication	Parkinson’s disease
Target	Paraoxonase 2 (PON2)
MoA(Mechanism of Action)	<ul style="list-style-type: none"> • Activation of PON2 1) Ameliorates the autophagic flux 2) Exhibits anti-oxidant effects 3) Decreases neuro-inflammation 4) Improves the mitochondrial function
Competitiveness	<ul style="list-style-type: none"> • Vutiglabridin is a first-in-class disease-modifying drug for treatment of Parkinson’s disease. • Levodopa is a standard of care for Parkinson’s disease, which relieves the symptoms, but it cannot prevent the loss of dopaminergic neurons. • Vutiglabridin has neuroprotective and therapeutic roles by activating autophagy flux and reducing oxidative stress, which differentiates it from Levodopa. • The safety of Vutiglabridin has been evaluated in humans during phase 1, and its efficacy in Parkinson’s disease will be evaluated in phase 2a.
Development Stage	Phase 2a
Route of Administration	Oral (QD, PO)